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Background: Recent reports that TLR4 and TLR7 ligands can synergistically trigger Th1 biased immune responses
suggest that an adjuvant that contains both ligands would be an excellent candidate for co-administration with
vaccine antigens for which heavily Th1 biased responses are desired. Ligands of each of these TLRs generally have
disparate biochemical properties, however, and straightforward co-formulation may represent an obstacle.
Results: We show here that the TLR7 ligand, imiquimod, and the TLR4 ligand, GLA, synergistically trigger responses in
human whole blood. We combined these ligands in an anionic liposomal formulation where the TLR7 ligand is in the
interior of the liposome and the TLR4 ligand intercalates into the lipid bilayer. The new liposomal formulations are
stable for at least a year and have an attractive average particle size of around 140 nm allowing sterile filtration. The
synergistic adjuvant biases away from Th2 responses, as seen by significantly reduced IL-5 and enhanced interferon
gamma production upon antigen-specific stimulation of cells from immunized mice, than any of the liposomal
formulations with only one TLR agonist. Qualitative alterations in antibody responses in mice demonstrate that
the adjuvant enhances Th1 adaptive immune responses above any adjuvant containing only a single TLR ligand
as well.
Conclusion: We now have a manufacturable, synergistic TLR4/TLR7 adjuvant that is made with excipients and
agonists that are pharmaceutically acceptable and will have a straightforward path into human clinical trials.
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Modern, effective vaccines rely on a combination of a
purified antigen against which an immune response is
desired and an adjuvant that triggers the innate immune
system to enhance the magnitude and quality of the gen-
erated immune response [1]. Producing new adjuvants
that can direct appropriate immunity is therefore becom-
ing key to vaccine design and groups have shown that
even in the context of the same antigen different out-
comes are achieved as a function of the co-administered
adjuvant [2]. Recent commercial approval of the CervarixW
vaccine that contains MPL, a defined TLR4 ligand, has
added momentum to the development of a new generation
of adjuvants [3].* Correspondence: dcarter@idri.org
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unless otherwise stated.The immune system has the inborn ability to recognize
molecular signatures carried by microbes. These Microbe
Associated Molecular Patterns (MAMPs) trigger any of an
array of receptor sensors in cells to alert the organism and
mobilize an appropriate immune response. MAMPs are
generally molecules that are vital to the microbe, perform-
ing key functions, but are not found in the host. Examples
include: lipopolysaccharides (LPS) found on the surface of
gram negative bacteria [4], RNAs produced as part of viral
replication [5], and flagellins that make up bacterial fla-
gella [6].
The Toll-Like Receptor (TLR) family of proteins is a
well characterized group of innate signaling receptors that
respond to a variety of MAMPs. TLRs 1,2, and 6 hetero-
dimerize and respond to lipopeptides; TLR3 binds double
stranded RNAs; TLR4 signals when triggered by LPSs;
TLR5 senses flagellins; TLR7 and 8 detect single stranded
RNAs and TLR9 responds to DNA with CpG motifs
[5,7-12]. To augment their ability to appropriately detect. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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source of the MAMP would be found; i.e. shed LPS is
picked up by lipopolysaccharide binding protein and
transported to the cell membrane where TLR4 is located
and the viral RNA sensors TLR3, 7, and 8 are located in
endosomes inside the cell where viral RNAs would be pro-
duced and their detection required [13,14].
TLR signaling and the resulting innate and adaptive
responses can be enhanced by synergy within the TLR
family [15] or by signals from TLR combined with those
from non-TLR innate sensors [16,17]. Within the TLR
family, TLR4 and TLR7 have been targeted by agonists
that are in late stage development [18,19] or are com-
mercial [20,21] and the two TLR show potential for
powerful synergism. This can be seen in increased mag-
nitudes of cytokine secretion, enhanced germinal center
formation, class switching and antibody diversity [22,23].
While the synergy that is induced is dramatic, the ago-
nists have to be co-localized and efforts to develop such
a combination adjuvant that can be manufactured cost
effectively at scale are still needed. Researchers in aca-
demic and company settings have started to produce ad-
juvants and vaccine nanoparticles that contain multiple
innate ligands [22,24-26] and standard vaccine prepara-
tions usually contain several TLR ligands since they are
derived from inactivated pathogens [27,28], but most of
these attempts are proof of concept exercises that have
not progressed due to the cost of manufacturing or the
poor definition of the relative ligand content. We report
here the development of a nanoliposome that co-
localizes TLR4 and TLR7 agonists and synergistically
enhances immune responses. The process used for
manufacture of the combination can be scalable and
commercially viable like similar liposomal formulations.Results
In vitro synergy of GLA and IMQ
To demonstrate that the selected ligands would syner-
gize, admixtures of the TLR7 agonist IMQ and the TLR4
agonist GLA were suspended in an aqueous formulation
and various dilutions tested for the ability to elicit cyto-
kine secretion from human whole blood. Although IMQ
itself is essentially insoluble in water, a proprietary com-
position by Invivogen facilitates aqueous suspension [29]
and, because both agonists act on the same cells, there is
no need for co-delivery in vitro. As shown in Figure 1,
the molecules synergistically elicit secretion of IL12p70
and IFNγ from cells. IL8 and MIP-1β were also deter-
mined and demonstrated enhanced secretion in the
combination group compared to the single ligands alone.
These data demonstrate that when the same cells are
stimulated by both ligands, synergistic signaling by the
innate immune system can occur.Manufacturing of the synergistic nanoliposome
After establishing that the molecules have the potential for
synergistic signaling, we set out to develop a manufactur-
ing process that would allow them to be co-localized in the
same particle. Liposomes comprise a versatile formulation
platform since they can be used to bring together active
molecules with different structural properties. For instance,
lipidic molecules such as MPLW or GLA can be incorpo-
rated in the phospholipid bilayer whereas small, more sol-
uble molecules may be encapsulated in the aqueous core.
Furthermore, several liposome-based formulations have
been approved for human use or reached advanced clinical
development in existing vaccine (e.g. Epaxal®, Mosquirix)
and drug (e.g. Ambisome®) products. Finally, liposomes
can be manufactured at small diameter (<200 nm), permit-
ting terminal sterile filtration and improved lymph node
targeting [30].
The formulation of IMQ presents a particular chal-
lenge due to its insolubility in aqueous solutions at
physiological pH [31,32]. In fact, IMQ has very low solu-
bility in most organic solvents, with the exception of
fatty acids which form the basis of the approved topical
cream containing IMQ called Aldara® [31]. IMQ is sol-
uble in acidic aqueous solutions and 0.1 M lactic acid-
based formulations of IMQ are in clinical development
for the treatment of bladder cancer [32-34]. Although
lactic acid is a widely used pharmaceutical excipient
[32,35], it does not prevent the systemic distribution of
IMQ; therefore, improving its vaccine adjuvant proper-
ties requires further formulation techniques to localize
the molecule in the body after administration [32,36].
We hypothesized that liposomes with a lactic acid core
would facilitate encapsulation of soluble IMQ while en-
abling the bulk aqueous phase external to the liposomes
to maintain a physiological buffer at close to a neutral
pH, which is desirable to minimize injection pain [37].
Moreover, liposomes should allow the intercalation of
the six acyl chains of GLA into the lipid bilayer.
Liposomes were manufactured using a thin-film method
wherein phospholipids and GLA were mixed with choles-
terol in organic solvent followed by evaporation of the
solvent under vacuum. Liposomes were rehydrated in
100 mM lactic acid containing 10 mg/ml IMQ, and soni-
cated in a water bath at ~60°C (above the phase transition
temperatures of the lipids) for ~1.5 – 3 hrs. The liposomes
were then transferred to a desalting column and the exter-
nal lactic acid solution was exchanged for phosphate-
buffered saline (PBS) at pH 7.2.
Different phospholipid compositions previously devel-
oped in our lab for formulation of GLA [38] were evalu-
ated as an initial formulation screen (Table 1), including
an anionic liposome (DPPC, DPPG, cholesterol; 18:2:5
weight ratio), a cationic liposome (DPPC, DPTAP, choles-
terol; 18:2:5 weight ratio), and a neutral liposome (DOPC,
Figure 1 Synergy between GLA and IMQ in vitro. Human whole blood was incubated with 2 μg/mL of GLA and 8 μg/mL of IMQ either alone
or in combination; the amount of secreted IL12p70 (top panel) or IFNγ (bottom panel) were then determined by ELISA. Means and standard error
of three donor values are shown. Similar trends were seen for MIP1β and IL8 as well (data not presented).
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concentrations were estimated at 50 and 55 mg/ml, re-
spectively, assuming no extra loss in the buffer exchange
and filtration steps. The cationic liposomes showed lower
encapsulation efficiency. Precipitation was evident in the
neutral DOPC-based liposomes and substantial IMQ was
lost upon filtration through a 0.2-μm membrane, even
though average particle size was small and encapsulation
efficiency was high. The anionic liposomes also showed
comparatively high encapsulation efficiency and much less







Anionic DPPC/DPPG/Cholesterol* 8 0.6 ± 0.1
Cationic DPPC/DPTAP/Cholesterol 1 0
Neutral DOPC/Cholesterol* 4 0.7 ± 0.2
*Some batches also contained GLA, although the presence of GLA did not have a s
mentioned. NM: not measured.concentration upon filtration may represent the propor-
tion of liposomes that are larger than 200 nm and not able
to pass through the membrane. Particle size and IMQ
concentration in three additional anionic liposome batches
prepared at a concentration of 38 mg/ml DPPC and
stored at 5°C demonstrated only 7 ± 5% and 9 ± 1%
change in particle size and IMQ concentration, respect-
ively, at the 12-month timepoint compared to immedi-
ately after manufacture. Finally, one of these three
batches also contained GLA, and its concentration
changed only ~8% over 12 months. Therefore, theQ
IMQ loading
efficiency (%)






6 ± 1 23 ± 12 151 ± 20 0.17 ± 0.07
0 NM 64 0.07
7 ± 2 45 ± 22 73 ± 23 0.20 ± 0.01
ignificant effect on the reported IMQ loading efficiency or the other properties
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terol were selected as the most suitable formulation for a
synergistic adjuvant containing GLA and IMQ.
Biophysical characterization of the liposome
Due to the insolubility of IMQ in aqueous solutions near
neutral pH, it was thought that the IMQ should be local-
ized in the acidic interior of the liposomes. We first
sought to confirm that the external lactic acid was re-
moved by the desalting column treatment by measuring
pH values before and after exposure to the desalting
column in liposomes containing IMQ, GLA, both of
the agonists, or neither. The pH values prior to buffer
exchange ranged from 2.5 - 3.5, whereas pH values after
buffer exchange were 6.7 - 6.9 (Table 2), indicating that
the lactic acid solution had indeed been replaced with
the buffered saline, although the pH values had grad-
ually decreased by an average of ~0.4 units when
measured one month after manufacture. After three suc-
cessive ultracentrifugation and wash steps, 74 ± 5% of
IMQ was recovered in the liposome pellet, whereas in an
IMQ control solution (not containing liposomes) the IMQ
remained in the supernatant. That more IMQ was not re-
covered in the pellet most likely represents a limitation of
the assay since negligible IMQ was present in the super-
natant. Together, these results indicate that the majority
of IMQ is localized in the lactic acid core of the liposomes.
An unexpected result of IMQ incorporation in liposomes
was the significantly higher particle size compared to
liposomes containing GLA or liposomes without TLR ag-
onists (Table 2), indicating that there may be some physi-
cochemical interaction between the lipids and IMQ. The
gradual decrease in pH over time is an important point
that may be addressable through further liposome
optimization. However, even if buffer exchange caused the
internal pH of the liposomes to change enough to affect
imiquimod solubility, the result could be the same type of
‘coffee-bean’ appearance that has been demonstrated for
the FDA-approved liposome formulation of the cancer
drug doxorubicin known as Doxil [39].
While IMQ loading efficiency is low (Table 1), it should
be noted that the loading mechanism is passive rather
than the more efficient, active loading methods based on
pH or ammonium sulfate gradients [40], although someTable 2 Comparison of liposome properties






GLA-LS 4 64 ± 12 0.23 ± 0.05
IMQ-LS* 4 160 ± 25 0.21 ± 0.10
GLA/IMQ-LS* 4 141 ± 5 0.14 ± 0.02
LS 4 70 ± 25 0.22 ± 0.04
*These liposomes are part of the 8 total IMQ-containing liposomes represented in raqueous solubility is a prerequisite of such loading
methods. By employing the mathematical model devel-
oped by Xu et al. [41], assuming 75 mM phospholipid
concentration, a monodisperse average particle size of
160 nm with polydispersity width of ± 35.2 nm, a bi-
layer thickness of 4.8 nm, and an average lipid molecular
area of 0.4 nm2 [41,42], the expected passive encapsula-
tion efficiency of IMQ is predicted to be ~24%. This
may be overly optimistic considering that the Z-ave
size value (i.e. 160 nm for IMQ-LS) is based on scatter-
ing intensity and thus biased towards larger particles,
and does not represent the true number-based size
mean which may be significantly smaller, thus reducing
the expected encapsulation efficiency. Nevertheless, it
should be possible to improve the loading efficiency of
the liposomes in the present work with further process
optimization.
In earlier work, we had demonstrated that GLA inter-
calated into phospholipid-emulsified oil at the oil/water
interface, causing a more negative zeta potential [38,43].
The same technique applied to anionic liposomes is not
as discriminatory due to the relatively high negative
charge of the liposomes themselves [38]; nevertheless,
given the insolubility of GLA and its affinity for phospho-
lipid structures [43,44], it is presumed that this TLR4 lig-
and localizes in the lipid bilayer in a similar manner to the
other phospholipids. Moreover, in a previous report we
employed in vitro bioactivity analysis and different order-
of-mixing techniques to indicate that GLA formulated in
anionic liposomes or oil-in-water emulsion is likely associ-
ated with the lipid particles rather than the bulk aqueous
phase [45].
Ongoing work in our lab is seeking to enhance loading
efficiency of liposomes containing IMQ by varying phospho-
lipid concentration and liposome preparation tech-
niques, such as replacing sonication with high pressure
homogenization to achieve more reproducible and uniform
particle size. However, even if loading efficiency remains
somewhat low, the cost efficiency of IMQ-containing lipo-
somes could still be quite favorable compared to other
TLR7 ligands given that IMQ is available at approximately
the same cost as phospholipid excipients (i.e. <$20/g) from
generic manufacturers, which is not the case with newer






81 ± 5 2.54 ± 0.06 6.73 ± 0.10
- 3.48 ± 0.01 6.84 ± 0.10
79 ± 10 3.53 ± 0.01 6.92 ± 0.01
- 2.60 ± 0.05 6.81 ± 0.07
ow 1 of Table 1.
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Once well-characterized, liposomal adjuvants were avail-
able that contained GLA, IMQ, or both, their ability to
mediate immune responses upon administration with
the recombinant malaria antigen, PbCSP, was evaluated.
The delivery system can potentially be used as an adju-
vant for any appropriate vaccine, but we selected this
malaria antigen as a model since we had had experience
with adjuvanted formulations of this protein. While Th2
responses, as indicated by antigen-specific IL-5 secre-
tion, were induced by immunization with empty or IMQ
only-containing liposomes, these were reduced to essen-
tially background levels with any GLA containing adju-
vant (Figure 2). Thus, no difference could be seen in the
ability to turn off IL-5 between the GLA alone and the
GLA + IMQ adjuvant. In contrast, both GLA containing
adjuvants increased Th1 responses, as indicated by
antigen-specific IFNγ secretion. While the GLA aloneFigure 2 Synergy adjuvant enhances Th1 responses. Mice were immun
liposomes (IMQ-LS), 5 μg GLA in liposomes (GLA-LS) or the combination ad
incubated with antigen. Panels A and B: ELISA determination of levels of s
number of specific cytokine secreting cells. Significant differences between
GLA liposomes were observed for the IFNγ ELISPOT (p-value < 0.0001), IL-5
differences for the IFNγ ELISA did not reach statistical significance. Symbols
Liposomes alone; ‡ = significantly higher than IMQ-LS; § = significantly high
Shown are means with standard error.liposomes resulted in robust secretion of IFNγ, the syn-
ergistic adjuvant was able to provide even higher IFNγ
responses (Figure 2).
To verify that the combination adjuvants resulted in a
biologically active Th1 biased adaptive response, anti-
body responses were determined as a function of adju-
vant (Figure 3). IgG1 in mice is reflective of a Th2
biased response and IgG2 is reflective of a Th1 bias. The
trends seen with the antigen-specific spleen cell responses
were reflected in the antibody responses: The adjuvants
with TLR ligands gave more IgG2. The synergistic adju-
vant gave the highest IgG2:IgG1 ratio consistent with the
most Th1 biased immune response (Figure 3, Panel C).
Conclusion
We report here the development of a synergistic adju-
vant that is manufacturable and combines TLR4 and
TLR7 ligands. We were able to develop a process byized with either PbCSP antigen, the liposomal carrier, 20 μg IMQ in
juvant (5 μg/20 μg, GLA/IMQ-LS), then spleen cells harvested and
ecreted cytokines. Panels C and D: ELISPOT enumerations of the
antigen alone, liposomes, IMQ liposomes, GLA liposomes, and IMQ/
ELISPOT (p-value = 0.0057), and the IL-5 ELISA (p-value = 0.0411). The
: * = significantly higher than Antigen alone;† = significantly higher than
er than GLA-LS. Single symbol: p < 0.05; Double symbol: p < 0.01;
Figure 3 Adaptive humoral responses induced by synergy adjuvants. Sera were collected from mice after the second immunization and PbCSP
antigen-specific IgG1 (Panel A) and IgG2c (Panel B) midpoint titers determined by ELISA. Consistent with the observed cytokine profile the combination
induced higher levels of IgG2c, a marker for Th1 immunity in mice. Panel C – the ratio in titers highlights the ability of the combination to
induce Th1 biased immunity. * = significantly higher than Antigen alone;† = significantly higher than Liposomes alone; ‡ = significantly higher
than IMQ-LS; Single symbol: p < 0.05; Double symbol: p < 0.01. Shown are means with standard error.
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ate the TLR4 ligand GLA at the phospholipid bilayer
interface and the TLR7 ligand IMQ in their interior.
The liposome co-localizes the agonists allowing same
cell activation of the external sensor TLR4 through
GLA and TLR7 through imiquimod. Therefore, the
same cell would experience simultaneous triggering of




Milled imiquimod (IMQ) was purchased from Chemagis
(Bnei Brak, Israel); imiquimod was also obtained from





were purchased from Avanti Polar Lipids Inc. (Alabaster,
AL). DOPC was also purchased from Lipoid (Newark,
NJ). Cholesterol, and ammonium phosphate mono- anddibasic were purchased from J.T. Baker (San Francisco,
CA). Lactic acid was purchased from Sigma-Aldrich
(St. Louis, MO). Phosphate buffered saline (PBS) at
pH 7.2 was purchased from Life Technologies (Grand
Island, NY).
Formulating liposomes
Liposome formulations were manufactured by first com-
bining phospholipids, cholesterol, and optionally, depend-
ing on the desired type of adjuvant, GLA, in chloroform:
methanol or chloroform:methanol:water, which was then
evaporated overnight using a Genevac EZ-2 Plus Evapor-
ator (Stone Ridge, New York). The dried components
were rehydrated in either 100 mM lactic acid with or
without 10 mg/ml IMQ, and then sonicated in a VWR
75D (West Chester, PA) or Crest Powersonic CP230D
(Trenton, NJ) water batch sonicator at ~60°C for 1.5 –
3 hrs, until the formulation appeared homogeneous and
translucent. This formulation was kept in a heated water
bath prior to transferring 2.5 ml to a separate disposable
PD-10 desalting column obtained from GE Healthcare
Bio-Sciences AB (Uppsala, Sweden). The columns arrived
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primed and subsequently eluted with 3.5 ml of PBS
(pH 7.2). The buffer exchange step induces a ~30% di-
lution of each formulation and is employed to exchange
the bulk aqueous phase external to the liposomes from
lactic acid to PBS, and to remove non-encapsulated IMQ.
GLA-LS formulations were then mixed with GLA-IMQ-
LS formulations in order to generate final formulations
with different doses of IMQ.Characterizing the formulations
Particle size of all liposomal formulations was moni-
tored by dynamic light scattering (DLS) using the Malvern
Instruments (Worcestershire, UK) Zetasizer Nano-S or
Nano-ZS. Samples were prepared at 1:100 dilutions by
combining 5 μl of each formulation with 500 μl of ultra-
pure water in a 1.5 ml polystyrene disposable cuvette. DLS
measurements were then made three times on each cu-
vette. Formulations containing GLA were analyzed by
reverse-phase high performance liquid chromatography
(HPLC) with charged aerosol detection (CAD) to deter-
mine GLA concentration as previously published [38]
except that in some cases the column employed was a
Waters XBridge C18 (Milford, MA). Formulations con-
taining IMQ were analyzed by UV–vis spectroscopy
(Hitachi U-3900H, Tokyo, Japan) to confirm IMQ con-
centration via absorbance at 307 nm. The pH of the
formulation before and after the buffer exchange was
also measured. Liposome formulations containing IMQ
were prepared in triplicates by combining 50 μl of sam-
ple with 950 μl of EtOH/HCl (98%/2%) into three sep-
arate disposable UV-cuvettes. IMQ concentration was
extrapolated from a linear 5-point standard curve. pH
was measured using a Mettler Toledo (Columbus, Ohio)
MP225 pH meter and an Orion Ross semi-micro 8103BN
pH probe obtained from Thermo Scientific (Waltham,
MA). A 3-point calibration was performed prior to meas-
urement with pH 4.00, 7.00, and 10.00 standard buffers.
To determine whether IMQ was encapsulated in the li-
posomes, ultracentrifuged samples were prepared by
transferring 200 μl of the liposome formulation into a
1.5 ml capacity ultracentrifuge tube and centrifuging at
160,000 × g at 4°C for three 3-hour cycles using an Optima™
MAX-XP Beckman-Coulter Ultracentrifuge (Indianapolis,
IN). The supernatant was removed after each of the first
two cycles and the pellet at the bottom of the tube was
washed, each time with 1 ml of PBS with gentle mixing,
followed by another 3 hours of ultracentrifugation at
160,000 × g at 4˚C, and subsequent removal of the super-
natant. The liposome pellet was then lysed with 1.05 ml
ethanol/concentrated hydrochloric acid (98%/2%), soni-
cated for ~5 mins, and diluted 1:20 in the same solvent
mixture for spectrophotometric analysis.In-vitro stimulation using a whole blood assay (WBA)
After obtaining informed consent, heparinized whole
blood was collected from healthy volunteers and 180 μl
plated directly into 96-well round-bottom tissue culture
plates. 20 μl of each formulation with the various innate
stimuli were then added giving final well volumes of
200 μl. Each stimulation condition was conducted in du-
plicate. IMQ from Invivogen was suspended in dH2O to
a concentration of 5 mg/ml. GLA-AF was manufactured
as described in Orr et al. [38] at a concentration of
1 mg/ml. IMQ and GLA were diluted in PBS prior to
addition, either separately and in combination, to blood,
which was then incubated at 37°C, 5% CO2 for 24 h.
After incubation, 100 μl of the plasma supernatant was
carefully extracted and cytokine content measured by
ELISA: Mip-1β (R & D Systems, Minneapolis, MN); IL-8,
IL-12p70, and IFNγ (eBioscience, San Diego, CA).Mice and immunizations
Plasmodium berghei circumsporozoite protein (PbCSP)
was expressed and purified from E. coli using the codon-
harmonized construct kindly provided by Dr. Evelina
Angov from the Walter Reed Army Institute of Research.
All animal protocols were approved by the IDRI institu-
tional animal care and use committee. Female C57BL/6
mice were purchased from Charles River Laboratories
(Wilmington, MA) and maintained in specific pathogen-
free conditions. Mice, 6–8 weeks of age, were immunized
intramuscularly three times in two-week intervals by injec-
tion at the base of the tail. For immunization, recombinant
protein was formulated with adjuvant to provide a total of
2 μg protein/injection with various doses of the adjuvant in
a total volume of 0.1 ml. The adjuvant doses corresponded
to 20 μg IMQ and 5 μg GLA for both the single and com-
bined adjuvants.Antibody analyses
Blood was collected from the retro-orbital sinus two
weeks after the second immunization and sera prepared.
Sera were stored at 4°C until antigen-specific antibody
responses were analyzed by ELISA. Briefly, ELISA plates
(Nunc, Rochester, NY) were coated with 1 μg/ml antigen
in 0.1 M bicarbonate buffer and blocked with 0.1% BSA-
PBS. Following washes in PBS/Tween, serially diluted
serum samples were added. After incubation and further
washes, either anti-mouse IgG-HRP, anti-mouse-IgG2c-
HRP or anti-mouse IgG1-HRP were added (all Southern
Biotech, Birmingham, AL). After incubation and wash-
ing, ABTS-H2O2 (Kirkegaard and Perry Laboratories,
Gaithersburg, MD) was added to the plates to reveal any
reactions, which were stopped by the addition of 0.1 N
H2SO4. Plates were analyzed at 405 nm (ELX808, Bio-
Tek Instruments Inc, Winooski, VT). Midpoint titers
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fits using the GraphPad Prism package V 6.03.
Cell preparations and antigen stimulation assays
Six weeks after the final immunization, spleens were re-
moved and single cell suspensions prepared. Mono-
nuclear cells were enumerated using a ViaCount assay
with a PCA system (Guava Technologies, Hayward, CA).
To determine overall cytokine production, spleen cells
were cultured at 2 × 105 cells per well in duplicate in a
96-well plate (Corning Incorporated, Corning, NY) in
RPMI-1640 supplemented with 10% heat-inactivated
FCS and 50,000 Units penicillin/streptomycin (Invitrogen),
in the presence of 10 μg/ml protein. Culture supernatants
were harvested after 4 days and IFNγ/IL-5 content deter-
mined by ELISA, according to the manufacturer’s instruc-
tions (eBioscience, San Diego, CA).
To determine the number of cells producing each
cytokine, multiScreen 96-well filtration plates (Millipore)
were coated with rat anti-mouse IL-5 or rat anti-mouse
IFNγ capture antibody (both eBioscience) and incubated
overnight at 4˚C. Plates were washed with PBS, blocked
with RPMI 1640 and 10% FBS for at least 1 h at room
temperature, and washed again. Spleen cells were then
added at 2 × 105 cells/well and stimulated with media or
antigen (10 μg/ml) for 48 h at 37˚C. The plates were
then washed with 0.1% PBS–Tween 20 and incubated
overnight with a biotin-conjugated rat anti-mouse IL-5
or IFNγ secondary antibody (eBioscience) diluted in
0.1% PBS–Tween 20/0.5% BSA. The filters were developed
using the VectaStain ABC avidin peroxidase conjugate and
Vectastain AEC substrate kits (Vector Laboratories, Burlin-
game, CA) according to the manufacturer’s protocol. The
reaction was stopped by washing the plates with deionized
water. Plates were dried in the dark, and spots were
counted on an automated ELISPOT reader (C.T.L. Series
3A Analyzer; Cellular Technology Ltd., Shaker Heights,
OH) and analyzed with ImmunoSpot software (Cellular
Technology Ltd).
Statistical methods
Five mice were immunized for each treatment with two
subsamples taken per mouse. These subsamples were
handled by treating mice within each treatment as a
nested random effect to allow the separation of the vari-
ability between mice from the variability within each
mouse. In order to test Th1 and Th2 responses in vivo
using ELISA determination of levels of secreted cyto-
kines and ELISPOT enumerations of the number of spe-
cific cytokine screening cells for both IL-5 and IFNγ
secretions, four one-way ANOVA tests were used. Each test
was used to compare mean differences between mice im-
munized with either antigen, the liposomal carrier, IMQ in
liposomes, GLA in liposomes, or the combination adjuvant.Tukey’s procedure was used to test pairwise compari-
sons between treatments if significant treatment effects
were found. Consideration of the variance estimates for
the nested factor indicated that, in all cases, the majority
of the variation in the data was due to variation between
mice rather than variation among the subsamples taken
from individual mice. All hypothesis testing was done at
the 95% level.
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